Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 May 6:9:2019-9-3.
doi: 10.7573/dic.2019-9-3. eCollection 2020.

Use of anti-CD20 therapy in follicular and marginal zone lymphoma: a review of the literature

Luis Miguel Juárez-Salcedo  1 , Diego Conde-Royo  2 , Keina Quiroz-Cervantes  3 , Samir Dalia  4
Affiliations
Review

Use of anti-CD20 therapy in follicular and marginal zone lymphoma: a review of the literature

Luis Miguel Juárez-Salcedo et al. Drugs Context. .

Abstract

The identification of the CD20 antigen in 1979 was the first step in what would become a therapeutic milestone opening the use of immunotherapy in hematological diseases. This protein is expressed on the surface of developing B cells, but not the early progenitors or mature plasma cells. In 1997, rituximab was approved by the Food and Drug Administration, and since then it has revolutionized the treatment of B-cell malignancies. It is used as a monotherapy and in combination, at induction, at relapsed, and also in maintenance. Indolent non-Hodgkin lymphomas are characterized by a long and non-aggressive course. In this group of lymphomas, rituximab represented a great therapeutic improvement, achieving lasting responses with few adverse effects. Nowadays, second-generation molecules are emerging that may have important advantages compared to rituximab, as well as biosimilars that represent an important cost-effective option.

Keywords: anti-CD20; biosimilars; immunotherapy; indolent non-Hodgkin lymphoma.

PubMed Disclaimer

Conflict of interest statement

Disclosure and potential conflicts of interest: The authors declare that they have no conflicts of interest relevant to this manuscript. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2020/04/dic.2019-9-3-COI.pdf

References

    1. National Cancer Institute. SEER cancer statistics review 1975–2013. Non-Hodgkin lymphoma. 2016. [Accessed June 21, 2017]. https://seer.cancer.gov/archive/csr/1975_2013/results_merged/sect_19_nhl....
    1. Vinjamaram S. Non-Hodgkin lymphoma treatment & management: approach considerations, management of indolent NHL, management of aggressive NHL. 2016. [Accessed January 10, 2019]. http://emedicine.medscape.com/article/203399-treatment#d7.
    1. Chao MP. Treatment challenges in the management of relapsed or refractory non-Hodgkin’s lymphoma—novel and emerging therapies. Cancer Manag Res. 2013;5:251–269. doi: 10.2147/CMAR.S34273. . eCollection 2013. - DOI - PMC - PubMed
    1. Maloney DG, Grillo-López AJ, Bodkin DJ, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin’s lymphoma. J Clin Oncol. 1997;15:3266–3274. doi: 10.1200/JCO.1997.15.10.3266. - DOI - PubMed
    1. McLaughlin P, Grillo-López AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16(8):2825–2833. doi: 10.1200/JCO.1998.16.8.2825. - DOI - PubMed